Abstracts between national culture and EQ-5D value sets. Method Rank correlation analysis is used to explore relationships between the relative values of a set of EQ-5D states and dimensions of national culture. The latter are taken from Hofstede's framework which operationalizes national culture in 5 dimensions. The analysis is carried out using data from the countries for which EQ-5D value sets and scores on Hofstede's dimensions of culture both exist: Results Some relationships among the EQ-5D dimensions and culture are observed. Eg. the culture dimension: Power-Distance correlates strongly with the EQ-5D dimension: Anxiety-Depression (Spearman's Rho for Power-Distance indices and TTO valuations of EQ-5D states 11112 and 11113 are 0.523 and 0.815 respectively). Strong and moderate relationships are observed among other culture dimensions (Individualism, Masculinity, Uncertainty-Avoidance) and EQ-5D dimensions (Pain, Self-Care). Discussion Different cultures appear to value EQ-5D dimensions differently. The correlation patterns observed in this study are generally consistent with a priori expectations based on the nature of the dimensions of culture and the EQ-5D model. This analysis demonstrates the potential of national culture in providing insight into the drivers of the relative values of EQ-5D dimensions for different countries, and in informing decisions about which EQ-5D value sets to use in situations where one does not exist. OBJECTIVES: To examine the risk of falls/fractures associated with atypical antipsychotic use compared to typical antipsychotic use in community dwelling older adults.
1
University of Georgia, Athens, GA, USA, 2 McMaster University, Hamilton, ON, Canada OBJECTIVES Primary study objective was to test whether individuals' responses to standard gamble (SG) questions do not depend on the duration of time spent in the health scenario presented ("timelessness"). Secondary objective of the study was to test the "timelessness" of VAS responses. METHODS Face-to-face interviews were conducted in a convenience sample of healthy volunteers (n = 59) aged 20 to 63. Individuals rated their preferences for three health states of varying post chemotherapy nausea and vomiting (PCNV) severity and current health, assuming six different time horizons. Repeated measures analysis of variance (RM-ANOVA) was conducted (SX6X4X2) to determine the affect of time (6 levels:3 days, 3 months, 1-, 5-and 20-year(s) and rest of life), health state (4 levels: mild, moderate and severe PCNV and current health), and method (2 levels: SG and VAS) on preference. RESULTS Results were analyzed using RM-ANOVA and latent growth modeling (LGM). Both showed that preferences decreased over time for SG and VAS (p < 0.05). For the RM-ANOVA, all main effects and interaction terms were significant (p < 0.05).
LGM showed acceptable fit and significant slope parameters for all PCNV. The slopes were decreasing over time. Significant latent variances for LGM showed that not all individuals change at the same rate over time (p < 0.05) CONCLUSIONS There is a clear advantage in the use of LGM over RM-ANOVA because LGM can evaluate group differences in addition to individual changes over time. For the majority of respondents the utility independence assumption for SG and VAS did not hold both at the group and the individual level. Similar to Bala et al (1999) and Franic et al (2003) the results of this study indicated preferences as measured by SG and VAS are not timeless. Regardless of the preference measure used: both SG and VAS yield higher preferences for shorter time horizons. 27,085; depression, N = 129,206; diabetes, N = 126,087; hypertension, N = 225,080; asthma, N = 56,172; fibromyalgia, N = 52,365) on the basis of 3 outcomes (total health care cost, emergency room [ER] visits, inpatient admissions) measured over a 1-year follow-up period. Goodness-of-fit statistics (chi-squared statistic for total health care costs and c-statistic for ER visits and inpatient admissions) were compared across age and sex-adjusted regression models for each individual RAM. RESULTS: A unique 3-digit ICD-9-CM code count that excluded 'rule-out' diagnoses consistently outperformed, i.e., had highest chisquared and c-statistics, every other RAM in every condition and outcome with the exception of the number of unique NDC codes, which performed the best for all outcomes in depression and fibromyalgia patients. The number of unique NDC codes was generally the second-best performing RAM across all outcomes. The CDS performed worst across every condition and outcome. CONCLUSIONS: Complex RAMs are subject to inconsistencies in their operationalization and application from a programming perspective. Across multiple acute and chronic conditions, the two simplest and programmatically-transparent RAMs were the most predictive measures of total health care cost, ER visits, and inpatient admissions.
PODIUM SESSION I: RISK MANAGEMENT STUDIES

RM1 COMPARATIVE PERFORMANCE OF RISK ADJUSTMENT MEASURES IN A SAMPLE OF COMMERCIALLY-INSURED PATIENTS UNDER AGE 65-TWO SIMPLE MEASURES OUTPERFORM CURRENT STANDARDS
RM2
IMPACT OF ADHERENCE WITH STATIN THERAPY ON HOSPITALIZATION RISK AND MORTALITY AMONG PATIENTS WITH DIABETES
Yang Y, Banahan BF, Pace PF University of Mississippi, University, MS, USA OBJECTIVES: The objective of this study was to evaluate the impact of adherence with statin therapy on diabetes-specific hospitalization and all-cause mortality among patients with diabetes enrolled in a state Medicaid program. METHODS: The authors conducted a retrospective cohort study of patients with diabetes who were continuously enrolled in a state Medicaid program from January 2002 to December 2004. The date of the first medication claim for statin during the first six months of 2002 was the index date. Adherence to statin was assessed within one year following the index date. Adherence was assessed using the proportion of days covered (PDC) and patients with a PDC of 0.8 or greater considered being adherent. The primary outcomes of interest were diabetes-specific hospitalization and all-cause mortality during the follow-up period (end of adherence measurement to December 31, 2004) . Multivariate regression analyses were performed to assess the impact of adherence with statin therapy on outcome measures. RESULTS: A total 10,839 patients were included in the study. Mean age 60.3 ± 10.0 years, 23.8% male, 76.2 female; 31.7% white, 50.4% black. At 12 months after the index prescription, only 23.9% of patients were adherent with their prescribed statin therapy. During follow-up After controlling for age, gender, race, prior hospitalization, and Charlson comorbidity index, patients who were adherent to statin therapy were 48.7% (OR: 0.513; 95%CI: 0.421-0.624) less likely to have diabetes-specific hospital admissions in comparison to nonadherent patients. Adherence with statin therapy had no statistically significant impact on allcause mortality (OR: 0.801; 95%CI: 0.454-1.412). CONCLUSIONS: Adherence with statin therapy was poor among patients with diabetes enrolled in a Medicaid program. Adherence with statin therapy was associated with significantly less risk for diabetes-specific hospitalization. Greater efforts are needed to facilitate diabetes selfmanagement behaviors to improve patient outcomes.
represented by 15,332 survey participants. Participants were classified according to CVD risk as diseased (history of coronary heart disease, angina, and/or myocardial infarction), at-risk (history of hyperlipidemia, hypertension, and/or diabetes mellitus), or low-risk (no history of any conditions). They were also classified according to the reported use of single-ingredient DSs including niacin, coenzyme Q10, fish oil, garlic, vitamin C, and vitamin E during the month prior to survey. Tests of moderation and confounding by age were performed. RESULTS: The prevalence of use of any of the six DSs increased with age. Odds ratios for any DS use for the at-risk and diseased groups, relative to the low-risk group, were 1.91 (95% CI: 1.67-2.17) and 2.25 (95% CI: 1.88-2.69), respectively. With adjustment for age, these became 1.32 (95% CI: 1.15-1.52) and 1.20 (95% CI: 0.99-1.44), respectively. There was no evidence of moderation (p = 0.123), though confounding was present (p < 0.001). CONCLU-SIONS: There is a potential for residual confounding by age in studies of CVD risk and DS use. After adequately controlling for age in this study, the relationship between CVD risk and DS use was greatly attenuated. The findings indicated different patterns of responses to cardiovascular disease risk between younger adults and older ones in terms of DS consumption. Awareness of the confounding effect of age in the association of CVD risk and DS use should be noted in clinical practice and health promotion.
PODIUM SESSION II: COST-EFFECTIVENESS STUDIES
CE1
COST-EFFECTIVENESS OF SWITCHING PATIENTS WITH TYPE 2 DIABETES FROM INSULIN GLARGINE TO INSULIN DETEMIR IN A CHINESE SETTING: A HEALTH ECONOMIC MODEL BASED ON THE PREDICTIVE STUDY
Yang L 1 , Christensen T 2 , White J 3 , Sun F 4 1 Peking University Health Science Center, Beijing, China, 2 Novo Nordisk A/S, Virum, Denmark, 3 Novo Nordisk, Zurich, Switzerland, 4 Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China OBJECTIVES: To evaluate the long-term cost-effectiveness of switching from insulin Glargine (IGla) to Insulin Detemir (IDet) in type 2 diabetes patients in the setting of Chinese tier 3 hospitals. METHODS: A published and validated computer simulation model of diabetes (the CORE Diabetes Model) was used to make the long-term (30 years) projection of health economic outcomes. Patient demographic information and clinical endpoints were derived from a subgroup analysis of the PREDICTIVE study. PREDICTIVE was a large, multi-centre, 6 months observational study assessing the safety and efficacy of IDet in everyday clinical practice. HbA1c was reduced of 0.59 % by switching from IGla to IDet. Baseline risk factors and racial characteristic data were obtained from Chinese cohort studies. The market retail prices of medications were calculated to estimate treatment costs. The diabetes management and complications costs were obtained from Chinese published data and adjusted to 2009 values using the Chinese Consumer Price Index. An annual discounting rate of 3% was used for both health and cost outcomes according to the recommendation of Chinese Pharmacoeconomics guideline. One-way sensitivities analysis was performed and illustrated that the results were robust. RESULTS: Conversion to IDet from IGla was projected to improve patient life expectancy by 0.09 year and 0.36 quality adjusted life years (QALYs). Treatment costs, and management costs were increased of 4,004 (84,047 vs 80,043), 243 (28,913 vs 28,670) Chinese Yuan (CNY) respectively. However, the costs of complications including CVD, renal, ulcer/amputation/neuropathy, eye and hypoglycaemia events were reduced by 4,931 CNY (89,628 vs 94,559), resulting in a total direct medical cost saving of 684 CNY when converting to IDet. CONCLUSIONS: Conversion to IDet from an IGla regimen improved life-expectancy and was a cost-saving treatment approach in a Chinese setting.
CE2
COST-EFFECTIVENESS OF SILDENAFIL IN THE MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION IN MEXICAN ADULT PATIENTS
Arreola-Ornelas H 1 , Rosado-Buzzo A 1 , García-Mollinedo L 1 , Dorantes-Aguilar J 1 , Muciño-Ortega E 2 , Mould-Quevedo JF 2 1 Links & Links, Mexico City, Mexico, 2 Pfizer S.A. de C.V., México City, Mexico OBJECTIVES: Pulmonary arterial hypertension (PAH) is a clinical condition that causes decreased exercise tolerance and heart failure. The aim of this study was to assess the cost-effectiveness of different drugs to manage PAH in adult, functional class III, patients, who have failed previously to calcioantagonists, from the health care payer's perspective. METHODS: A five-state Markov model was performed to estimate one year costs and health consequences (1-month cycles). Effectiveness measures were quality-adjusted life years (QALY's) gained, as well as reduction in hospital length of stay (LOS) and discontinuation rate due to adverse events. Transition probabilities were obtained from a meta-analysis involving national and international published literature. Doses of comparators used in the assessment were sildenafil (60 mg/day); bosentan (250 mg/day); sitaxsentan (100 mg/day) and ambrisentan (5 mg/day, reference alternative). Resource use and costs were obtained from hospital records (n = 110) from the Social Security Mexican Institute. Costs include hospital stay, laboratory and respiratory function tests, imagenology, drugs and adverse events management. The model was validated according to international guidelines. Sensitivity analyses were performed employing bootstrapping techniques and acceptability curves were constructed. RESULTS: Per patient associated costs for sildenafil, bosen-tan, sitaxsentan and ambrisentan were [CI 95%]: US$16, 840 [US$16, 176] , US$38, 068 [US$37, 497] , US$40, 203 [US$39, 647] and US$26, 146 [US$25, 479] , respectively. Sildenafil is associated to the highest gain in QALY's: 0.1 [−0.01-0.22], as well as to the main reduction in discontinuation rate: 89.25 [89.11%-89.4%] and reduction in LOS: 8.64 days [8.53 days-8.75 days], respectively. In consequence, sildenafil represents the most attractive therapy to manage PHA in terms of cost-effectiveness. CONCLUSIONS: In the Mexican institutional setting, sildenafil demonstrated to be a cost-saving therapy to manage PHA in adult, functional class III patients. These results should be taken into account by Mexican health professionals to generate efficient resource allocation strategies. Tables; for deceased patients, only the number of survival days as reported in the CRF, was retained. Per patient survival was then weighed using a predicted death rate based on individual Apache II scores, to account for disease severity. Univariate sensitivity analyses on costs and outcomes and 2000 Bootstrap simulations were run to test CEA's results. RESULTS: Based on the expected number of survival years (PMX-CT 8.24/patient, CT 4.69/patient), the mean difference in survival yielded an expected increase of 3.55LYG/patient for PMX-CT, at the additional cost of 313,411/patient with a mean ICER of 33,774/LYG and a median ICER of 32,776/LYG. Results of the base-case CEA were confirmed by all sensitivity analyses with ICER values always well below commonly accepted value thresholds.CONCLU-SIONS: PMX-CT vs. CT is a cost-effective intervention for treatment of severe abdominal sepsis and septic shock and should be considered for use in the Italian NHS' hospital setting.
CE3
COST-EFFECTIVENESS OF POLYMYXIN B IMMOBILIZED FIBER COLUMN AND CONVENTIONAL MEDICAL THERAPY IN THE MANAGEMENT OF SEVERE ABDOMINAL SEPSIS IN ITALY
CE4 A PRELIMINARY COST-EFFECTIVENESS ANALYSIS OF TARGETED VACCINATION POLICIES TO MITIGATE THE IMPACT OF THE H1N1 PANDEMIC IN THE US
Hettle R, Reason T Heron Evidence Development Ltd, Luton, Bedfordshire, UK OBJECTIVES: Under the circumstances of a severe pandemic and constrained research and manufacturing capacity, the need to appropriately deploy vaccination stockpiles becomes critical. The objective of this study was to provide insight into the most cost-effective vaccination strategy when under constrained circumstances. METHODS: A deterministic and compartmental SIR (Susceptible-Infected-Removed) cost-effectiveness model was developed from a US CDC perspective using Microsoft Excel. The model consists of 6 distinct age groups, integrated by a contact matrix. The infectivity of the pandemic was based on reported CDC estimates, with the model calibrated accordingly. A 75% vaccination efficacy was used, consistent with previous studies. Under the assumption of stockpiling 50 million doses of vaccine, vaccination strategies were assessed in terms of infections avoided during the estimated 17 month period of the pandemic. The scenarios included strategies targeted to specific age groups: individually targeted age groups, groups under 20, over 20, 20-59 and 0-12 and 60+ combined. Costs were limited to vaccine acquisition, with the total rate of vaccination per day estimated at 741,935. For the base case, we initiate the pandemic in May 2009 and began vaccination in October. Sensitivity analysis on the initiation of vaccination was also assessed. RESULTS: With no vaccination, a basic reproduction number of 1.3 and infectious period of 4.5 days yielded an attack rate of 27.7%.The cost-effectiveness of targeted vaccination ranged from $4.87 (13-19 years) to $67.05 (65+) per infection avoided. Under the criteria of exhausting vaccine supplies, the most cost-effective strategy was to target those under 20 years old ($10.77 per infection avoided). Initiating vaccination earlier during a pandemic marginally improved costeffectiveness, while delayed vaccination resulted in substantially reduced cost-effectiveness. CONCLUSIONS: Administering vaccinations to those aged under 20 years is the most cost-effective strategy. All vaccination policies initiated after the peak of the pandemic, were less cost-effective.
